Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.
about
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza VaccinesInfluenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsA consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza virusesDivergent H7 immunogens offer protection from H7N9 virus challenge.Turkey versus guinea pig red blood cells: hemagglutination differences alter hemagglutination inhibition responses against influenza A/H1N1.Antigen-specific H1N1 influenza antibody responses in acute respiratory tract infections and their relation to influenza infection and disease courseHuman responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangementsImmunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment.Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.Development of a vaccine against pandemic influenza viruses: current status and perspectives.H7N9 influenza virus neutralizing antibodies that possess few somatic mutationsCodon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickensEfficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice.Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses.Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccinesThe impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titersSystem-Wide Associations between DNA-Methylation, Gene Expression, and Humoral Immune Response to Influenza Vaccination.Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine.DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.Technical transformation of biodefense vaccines.Pathogenesis of swine influenza virus (Thai isolates) in weanling pigs: an experimental trial.Granzyme B ELISPOT assay to measure influenza-specific cellular immunityComparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse.Recombinant Marek's Disease Virus as a Vector-Based Vaccine against Avian Leukosis Virus Subgroup J in Chicken.Gene signatures associated with adaptive humoral immunity following seasonal influenza A/H1N1 vaccination.The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methodsCross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.DNA immunization.Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay.Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes.DNA-epitope vaccine provided efficient protection to mice against lethal dose of influenza A virus H1N1.DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses.A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.Identification of Aim2 as a sensor for DNA vaccines.
P2860
Q27478355-83DF056E-F929-473B-9C07-A88AFCA2C402Q28742787-CDE0A52F-798E-468F-89A5-47FA7A1459AAQ30228657-F888AD02-399F-4533-981C-3B22F5E88D33Q30358196-D5F63DF8-85C4-4063-BB4E-959321098FF1Q30362094-D6B47A5C-1915-4D07-9C03-23AF94E4A257Q30363631-FE0D1EC9-BDE4-46A1-90CD-FA97290CBFC7Q30364187-831E3000-E58A-408B-82DE-CAFDEE261FD1Q30367637-D4B95858-4200-4063-85D3-44ABF2B29E2BQ30368929-93B7F805-20CF-466C-97EB-720ABB7D8FFBQ30369828-F37FAD1E-A622-4CFE-A6CB-E6D63690D4FCQ30373784-C2176042-C3E6-4FAE-A513-B12128EB72B9Q30385356-7739956A-8847-4713-AE93-9826D46B6BB5Q30392246-55E921DC-D74B-4DC4-B187-BAB812ED36E7Q30400895-E11C63DC-756F-49F1-91E3-6174758AF8E2Q30411149-4738E232-7934-4D41-A779-26F6AD5EC519Q33698142-4CCCA899-2C27-4A5E-8D39-C946263920B1Q33883224-B3A42132-1592-4292-8776-5AAAE63F94CEQ34354440-8F574582-8673-448F-9B54-059F633F7870Q35225020-84185191-8035-4D68-AF7F-C785C369EFF4Q35826610-C1BB9478-3CC6-46FD-80F7-B4D34F5E8510Q35887557-819A6377-EC4F-4CA2-A49F-06072B8A911AQ35975551-DC1E8AB2-BFCE-4B1F-8402-2FF406252D14Q36109563-4C142836-49B2-4915-9CF7-3C588955B16EQ36694841-EBD0ADC1-BF39-4074-ACD1-574FADD09107Q37058898-EB85AC2E-AFB8-4449-A160-ADBE16BE3C2FQ37182114-95D4B625-F480-4667-A7E8-2DE2DECC7B91Q37341436-DABF21AB-71D7-48A2-901C-42ABC663827DQ37411209-C22ACD56-C09C-411A-84C6-2A7ACD8C643FQ37450167-A9128358-6AAB-47B6-8AF0-39A6B5820BF1Q37463459-7637136D-8952-4934-884A-72B31F1CF140Q37464882-F76FFD42-4FDD-4B13-A205-E53D9A411646Q37530450-CE7B980B-BAD4-4AE8-86F1-82A1296577BBQ37576264-5841E6CF-C3A3-47DF-BB6D-D175180B9A74Q37629980-9F3A6059-1E6D-4985-94B3-F5D5FD05C2A5Q38875509-5DE85EC2-14E1-4413-9077-AF20E967BD2BQ39025132-3266AF3F-5FED-4BFD-980B-62E47549D85DQ39036094-21A0A922-5C49-4EA4-9115-D5B1EB7FC4FBQ39311178-EE05BEE6-3AD4-4C7E-B7DC-E81AD9A12071Q40294097-76823AA5-1FAB-4FB7-B653-DFD6D6B8AFECQ41609361-DF0B8B20-1367-40C1-99FD-BD7A271B0A57
P2860
Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Hemagglutinin (HA) proteins fr ...... don-optimized HA DNA vaccines.
@en
Hemagglutinin
@nl
type
label
Hemagglutinin (HA) proteins fr ...... don-optimized HA DNA vaccines.
@en
Hemagglutinin
@nl
prefLabel
Hemagglutinin (HA) proteins fr ...... don-optimized HA DNA vaccines.
@en
Hemagglutinin
@nl
P2093
P2860
P356
P1433
P1476
Hemagglutinin (HA) proteins fr ...... don-optimized HA DNA vaccines.
@en
P2093
Christopher Parker
Jessica Taaffe
Shixia Wang
P2860
P304
11628-11637
P356
10.1128/JVI.01065-06
P407
P577
2006-09-20T00:00:00Z